Review

Atypical Ductal Hyperplasia of the Breast: A Comprehensive Review

Frank Chen, MD, PhD;[1]* Evan Liu[2]

[1] *Buffalo Clinical Lab, Quest Diagnostics, One Sylvan Parkway, Buffalo, NY*
[2] *Walt Whitman High School, 7100 Whittier Boulevard, Bethesda, MD*

Atypical Ductal Hyperplasia (ADH) is a histopathological diagnosis frequently encountered in breast tissue biopsies. It stands as a premalignant lesion characterized by cellular proliferation and architectural distortion, positioning itself within the spectrum between benign hyperplasia and ductal carcinoma in situ (DCIS). Notably, ADH bears significant implications for subsequent breast cancer risk. This review delves into the clinical significance, histological features, and molecular alterations of ADH, delving into its association with future breast cancer risk, optimal management approaches, and the impact on patient care. Continued research and collaboration are imperative for optimizing patient care. Throughout this discussion, current research findings are corroborative, underscoring the critical need for precise diagnosis and tailored follow-up to enhance patient outcomes.
[N A J Med Sci. 2023;16(1):006-013. DOI: 10.7156/najms.2023.1601006]

Key Words: *Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS), Breast cancer*

INTRODUCTION

Breast cancer is a significant global health concern, representing both a medical challenge and a source of distress for millions of individuals. In 2020 alone, over 2 million new cases of breast cancer were diagnosed worldwide, and it ranked as the fifth leading cause of cancer-related deaths, claiming nearly 685,000 lives.[1] While the overall burden of breast cancer is substantial, the spectrum of breast lesions encompasses a diverse range of abnormalities, some of which carry uncertain malignant potential and pose unique diagnostic and management dilemmas.[2]

Among these lesions is Atypical Ductal Hyperplasia (ADH), a breast condition that occupies a distinct place within the landscape of breast pathology. ADH, characterized by the proliferation of abnormal cells within breast ducts, shares histological similarities with low-grade ductal carcinoma in situ (DCIS) but is distinguished by its smaller size or extent.[2,3] ADH is frequently detected through mammographic screening, typically following a minimally invasive breast biopsy.[4] Its diagnosis, however, raises questions regarding its clinical significance, the risk of progression to invasive cancer, and the most appropriate management strategies.[3]

This comprehensive review seeks to provide a thorough examination of ADH. It will commence by delving into the epidemiology of ADH, shedding light on its prevalence, incidence trends, and distribution across different age groups and genders. Concurrently, it will scrutinize the risk factors associated with ADH, categorizing them into non-modifiable and modifiable factors, and elucidating the relationships between genetics, reproductive history, hormonal therapy, and lifestyle choices in shaping ADH risk.[1,5] Furthermore, it will investigate the mechanisms by which these risk factors exert their influence on the development and progression of ADH, offering insights into the complex biological pathways that underlie this condition. Ultimately, this review underscores the imperative for sustained research efforts and collaborative endeavors to enhance the understanding and management of ADH.

EPIDEMIOLOGY

Prevalence and Incidence Rates

ADH is frequently encountered in breast cancer screening programs, primarily through mammography and subsequent biopsy.[6] In breast screening, ADH is often diagnosed incidentally while evaluating mammographic abnormalities, such as microcalcifications. The prevalence of ADH varies among different screening populations, ranging from approximately 0.1% to 2.4% of all screened individuals.[6,7,8]

The incidence of ADH reflects the frequency of new cases diagnosed each year. This metric is important as it provides insights into the temporal trends of ADH diagnosis and its potential association with changing screening practices. The incidence of ADH is influenced by several factors, including the implementation of digital mammography and the evolving criteria for biopsy recommendations.[9]

Received: 09/03/2023; Revised: 11/20/2023; Accepted: 11/25/2023
***Corresponding Author:** Medical Director, Buffalo Clinical Lab, Quest Diagnostics, One Sylvan Parkway, Buffalo, NY 14226. Tel: 716-515-5406. (Email: dr.frankxchen@gmail.com)

Several factors contribute to the varying prevalence and incidence rates of ADH. These include differences in screening protocols, biopsy practices, and population demographics. The use of digital mammography, which offers improved sensitivity in detecting microcalcifications associated with ADH, has influenced its increased detection rates in recent years.[6,9]

Moreover, the criteria for recommending biopsy for suspicious mammographic findings, including ADH-associated microcalcifications, have evolved. This has led to changes in the prevalence and incidence of ADH over time, emphasizing the importance of keeping screening guidelines updated.[9]

The detection of ADH has clinical implications for individuals identified with this lesion. While ADH itself is not malignant yet, its presence is associated with an increased risk of subsequent breast cancer development.[10] Hence, understanding the prevalence and incidence rates of ADH can aid in risk assessment and the formulation of personalized surveillance and management strategies for affected individuals.

Regional and Demographic Variations

ADH prevalence and incidence rates vary geographically, often mirroring disparities in healthcare access and screening utilization. Evidence from several studies reveals substantial geographic variations in ADH rates within countries.[6] For example, urban areas with better access to breast cancer screening facilities tend to have higher ADH detection rates than rural regions. International comparisons highlight differences in ADH prevalence and incidence across countries. Variations in breast cancer screening programs, healthcare infrastructure, and cultural factors contribute to these differences. For instance, countries with comprehensive mammography screening programs tend to diagnose ADH more frequently.[1]

Age and gender play significant roles in ADH diagnosis. While ADH primarily affects women, its prevalence varies among different age groups.[5] In younger women, ADH may be less common, but when detected, it often raises concerns due to its association with an elevated risk of subsequent breast cancer. Racial and ethnic disparities in ADH prevalence and incidence have been documented, highlighting the influence of genetics, socio-economic factors, and healthcare access. Studies indicate variations in ADH rates among racial and ethnic groups, with some populations experiencing higher prevalence.[5,6] These disparities underscore the importance of addressing healthcare inequalities in ADH detection and management.

Regional and demographic variations in ADH have significant clinical implications. Understanding these variations helps tailor screening and management strategies to specific populations.[11] Healthcare providers must be aware of the disparities in ADH rates to ensure equitable access to screening and follow-up care. Regional and demographic factors can influence an individual's risk of ADH. For example, women from regions with higher ADH prevalence may face an elevated risk of ADH diagnosis, necessitating personalized risk assessment and surveillance strategies.[5,6] Variations in ADH rates among age groups and racial/ethnic populations may necessitate adjustments to screening guidelines. Tailored guidelines can ensure that individuals at higher risk receive appropriate screening and follow-up, thereby improving early detection and outcomes.[5,7] Addressing regional and demographic disparities in ADH diagnosis and management is essential for achieving health equity. Initiatives aimed at reducing disparities, such as improving access to screening services and increasing awareness among underserved populations, can contribute to more equitable healthcare delivery.[5,6]

RISK FACTORS

Table 1. Non-modifiable, modifiable, and environmental risk factors for ADH.

Non-modifiable	Modifiable	Environmental
Gender and Age	Hormone Replacement Therapy (HRT)	Radiation Exposure
Family History	Oral Contraceptives	Chemical Exposures
Genetic Mutations	Reproductive Factors	Lifestyle and Environmental Toxins
History of Breast Lesions	Obesity	Diet and Nutrition
Hormonal Factors	Alcohol Consumption	
	Physical Activity	
	Diet	
	Artificial Light Exposure	
	Smoking	

Non-modifiable Risk Factors

While some risk factors for ADH can be modified through lifestyle changes, there exist non-modifiable factors that individuals have limited control over. Understanding these non-modifiable risk factors is crucial for risk assessment, prevention, and early intervention.

Gender and Age

ADH predominantly affects women, and it is exceptionally rare in men.[12,13] Female breast tissue undergoes continuous hormonal changes throughout life, making it more susceptible to ADH development. ADH is more commonly diagnosed in older women, with the risk increasing as age advances.[7,13] Postmenopausal women are at a higher risk, possibly due to hormonal fluctuations and cumulative exposures over time.

Family History

A family history of breast cancer, particularly among first-degree relatives (such as mother, sister, or daughter), is a strong non-modifiable risk factor for ADH.[5,13] Genetic factors and shared environmental influences may contribute to this association. Even a history of breast cancer among second-degree relatives (such as aunts or grandmothers) may confer a moderate increase in ADH risk.[5] Genetic predisposition could be a contributing factor.

Genetic Mutations
Inherited genetic mutations, such as those in the BRCA1 and BRCA2 genes, significantly elevate the risk of ADH and breast cancer.[9,13] Individuals with these mutations have a higher likelihood of developing ADH at a younger age. Beyond BRCA mutations, various other genetic variants have been associated with ADH risk.[14] Ongoing research aims to uncover additional genetic factors contributing to ADH susceptibility.

History of Breast Lesions
A previous diagnosis of ADH increases the risk of developing ADH again in the same breast or the contralateral breast.[9] Patients with a history of ADH should undergo regular surveillance. Some benign breast conditions, such as proliferative breast disease without atypia, may also elevate ADH risk.[9,13] These conditions may share underlying molecular pathways with ADH.

Hormonal Factors
Early onset of menstruation (menarche) has been linked to a slightly increased risk of ADH.[13] Hormonal changes during puberty may play a role in ADH development. The age at which menopause occurs may influence ADH risk, with late menopause associated with a higher risk. Prolonged hormonal exposures could contribute. The use of HRT, particularly estrogen and progesterone combinations, has been associated with an increased risk of ADH.[1]

Modifiable Risk Factors
Understanding modifiable risk factors for ADH is essential for developing preventive strategies and lifestyle interventions. These factors, unlike non-modifiable ones, can be altered through behavioral changes and medical interventions.

Hormone Replacement Therapy (HRT)
Estrogen-only hormone replacement therapy (HRT) is associated with an increased risk of ADH.[1] Women considering HRT should discuss the risks and benefits with their healthcare providers, especially if they have other risk factors. Combination HRT, which includes both estrogen and progesterone, has been linked to a higher risk of ADH. The type, duration, and dosage of HRT may influence ADH risk.

Oral Contraceptives
Current use of oral contraceptives has been associated with a slightly elevated risk of ADH.[5] However, the increased risk is relatively modest.

Reproductive Factors
Nulliparity, or never having given birth, is a modifiable risk factor for ADH.[5] Women who have not had children may be at a slightly higher risk. Women who delay childbirth until age 30 or older may face an increased risk of ADH. Earlier pregnancies may have a protective effect.

Obesity
Higher BMI is associated with an elevated risk of ADH.[5] Obesity can lead to hormonal changes that promote ADH development.

Alcohol Consumption
Excessive alcohol consumption is a modifiable risk factor for ADH.[1] Reducing alcohol intake may help mitigate this risk.

Physical Activity
A sedentary lifestyle is associated with an increased risk of ADH.[1] Engaging in regular physical activity may reduce this risk.

Diet
Dietary factors, including a diet high in saturated fats and low in fruits and vegetables, may contribute to ADH risk.[1] Adopting a balanced and healthy diet could be protective.

Artificial Light Exposure
Exposure to artificial light at night, such as from electronic screens, may disrupt circadian rhythms and affect hormonal regulation.[1] Limiting nighttime light exposure may have a positive impact.

Smoking
While smoking is not a direct risk factor for ADH, it is associated with a higher risk of breast cancer.[1,7] Smoking cessation is advisable for overall breast health.

Environmental Factors
Environmental factors play a significant role in breast health and may contribute to the development of ADH. These factors encompass various exposures and external influences that can impact breast tissue and contribute to disease risk.

Radiation Exposure
Exposure to ionizing radiation from medical procedures, such as diagnostic imaging or radiation therapy, has been associated with an increased risk of ADH.[13] This highlights the importance of minimizing unnecessary radiation exposure during medical care. Prolonged exposure to environmental radiation, such as living in areas with high natural background radiation, may also contribute to breast cancer risk, including ADH. Monitoring and mitigating exposure in high-risk regions is advisable.

Chemical Exposures
Environmental chemicals with endocrine-disrupting properties, such as bisphenol A (BPA) and phthalates, have been studied in relation to breast health.[1] These chemicals may mimic or interfere with hormonal signaling, potentially influencing ADH risk. Exposure to pesticides and herbicides has been investigated as a potential risk factor for ADH and breast cancer. Agricultural workers and those living in agricultural regions may face higher exposure risks.

Lifestyle and Environmental Toxins
Exposure to air pollutants, including fine particulate matter and polycyclic aromatic hydrocarbons (PAHs), has been linked to breast cancer risk.[1] Reducing exposure to air pollution through environmental policies and lifestyle changes

may be beneficial. Certain occupational exposures, such as working in industries involving chemicals or solvents, have been explored as potential contributors to breast cancer risk.

Diet and Nutrition

The presence of contaminants in food, such as pesticides, heavy metals, and hormone-disrupting chemicals, may have implications for breast health.[1] Consuming organic and minimally processed foods may help mitigate exposure to these contaminants. Dietary choices, including the consumption of processed foods, high-fat diets, and foods with added hormones, can also influence breast health. Adopting a balanced and nutrient-rich diet may support breast health.

PATHOLOGICAL AND MOLECULAR FEATURES

Histological Characteristics

ADH is characterized by abnormal cell proliferation within the breast ducts, resembling low-grade ductal carcinoma in situ (DCIS). However, unlike DCIS, ADH is typically limited in size and extent, and its cells have not invaded the basement membrane.[7]

Histologically, ADH often manifests as ductal structures lined with cells exhibiting atypia (**Figure 1** and **Figure 2**). These cells may exhibit various architectural patterns, including cribriform, micropapillary, and solid growth patterns.[2] The presence of cellular atypia is a hallmark of ADH. Cellular atypia in ADH is characterized by nuclear enlargement, irregularities in nuclear shape, and prominent nucleoli.[7]

Accurate histological diagnosis of ADH is crucial, as it often necessitates different management strategies compared to benign lesions. The differential diagnosis includes various benign breast lesions, such as usual ductal hyperplasia (UDH), and early-stage malignancies like low-grade DCIS.[15] In some cases, there may be discordance between the radiological appearance of a lesion and its histological characteristics. This discordance can pose challenges in diagnosis and management decisions, highlighting the importance of a multidisciplinary approach.[12,16]

Immunohistochemistry can provide valuable insights into the histological features of ADH. Expression of markers such as Ki-67, p16, ER, PR, and HER2 can help characterize ADH and differentiate it from benign lesions or more advanced breast lesions.[2,3] Microcalcifications observed on mammography often lead to the discovery of ADH. These calcifications may appear as tiny punctate or linear deposits and can aid in identifying ADH on histological examination.[12,16]

ADH can present with histological variants and subtypes. For example, papillary ADH is characterized by papillary architecture and is often associated with microcalcifications. Recognizing these variations is essential for accurate diagnosis.[2,12,16] Certain histological characteristics, such as the extent of atypia and architectural patterns, may influence the likelihood of malignant transformation.[10,15]

Histological examination remains the gold standard for diagnosing ADH and understanding its characteristics. Accurate identification of histological features, grading, and differentiation from other breast lesions is essential for guiding appropriate management strategies.[2,3,6,7,10,14,15]



Figure 1. Atypical Ductal Hyperplasia (ADH). Two foci of ADH show partial cribriform pattern and focal solid pattern. Hematoxylin-eosin, original magnifications x 100.



Figure 2. Atypical Ductal Hyperplasia (ADH). In both panel 2A and 2B, ADH displays partial cribriform pattern. Hematoxylin-eosin, original magnifications x 400.

Molecular Alterations and Profiling

Genetic Alterations

Genetic studies have identified several chromosomal alterations associated with ADH. Loss of heterozygosity (LOH) at specific loci, such as 16q, is a common genetic event in ADH, often leading to a loss of tumor suppressor genes.[18,19,20] Gain of genetic material on certain chromosomes, like 1q, has been observed in ADH lesions. These gains may contribute to the molecular changes associated with ADH.[7,9,13]

Genetic profiling has revealed similarities between ADH, Ductal Carcinoma in Situ (DCIS), and invasive breast carcinoma. Shared genetic alterations suggest a continuum of progression from ADH to more advanced stages of breast cancer.[6,7,9,13,14]

Molecular Subtypes

Molecular subtyping has gained prominence in breast cancer research. Understanding the molecular subtypes of ADH lesions can provide insights into their behavior and progression risk. Subtypes such as luminal A, luminal B, HER2-enriched, and basal-like have been identified in ADH lesions.[2,6,7]

Molecular profiling of ADH lesions has the potential to predict which lesions are more likely to progress to invasive breast cancer. Identifying high-risk ADH subtypes can guide clinical decisions regarding surveillance and treatment.[10,15] While molecular profiling holds promise, there are challenges such as intertumoral heterogeneity and the need for standardized assays. Addressing these challenges is essential to ensure the accuracy and clinical relevance of molecular profiling in ADH.[6,7,10]

Biomarkers

Ki-67 (Mib1)

Ki-67 (Mib1) is a proliferation marker often assessed in ADH lesions.[6,7,9,13] Elevated expression of Ki-67 (Mib1) indicates increased cellular proliferation, suggesting a potential for progression to more advanced stages of breast cancer. High Ki-67 (Mib1) expression in ADH lesions may serve as indicators of increased risk for progression. These markers can aid in risk stratification and influence clinical decision-making, including the consideration of more aggressive treatments or closer surveillance.

E-cadherin

E-cadherin is an adhesion molecule crucial for maintaining tissue integrity.[6,7,9,13] Its loss or aberrant expression in ADH lesions can disrupt cell-cell adhesion, potentially facilitating the invasion of neighboring tissues.

microRNAs (miRNAs), Long Non-coding RNAs (lncRNAs), and Circular RNAs (circRNAs)

miRNAs, lncRNAs, and circRNAs are RNA molecules involved in the regulation of gene expression.[3,14] Dysregulation of these molecules in ADH lesions can impact cellular processes, potentially influencing disease progression.[21,22,23]

Tumor-infiltrating lymphocytes (TILs)

TILs represent immune cells that infiltrate the tumor microenvironment.[3,14] Their presence in ADH lesions can reflect the host's immune response to abnormal cells. The density and composition of TILs in ADH lesions have been associated with progression risk. High TIL levels may signify an active immune response against precancerous cells.

Tumor Mutational Burden (TMB)

TMB measures the number of mutations in a tumor's DNA.[3,14] Higher TMB in ADH lesions can signify genomic instability and potential for progression. TMB measures the number of mutations in a tumor's DNA. Higher TMB in ADH lesions can signify genomic instability and potential for progression.

Incorporating these specific biomarkers into the assessment of ADH lesions can enhance the ability to predict progression and inform clinical decisions.[3,6,7,9,13,14] These markers offer

valuable insights into the molecular and cellular changes associated with ADH and its potential to evolve into invasive breast carcinoma.

DIAGNOSTIC CHALLENGES

Histopathological Criteria and Variability

The histopathological evaluation of ADH relies on the identification of specific morphological features, including architectural and cytological characteristics.[6,7,9,13] However, the interpretation of these features can exhibit substantial interobserver variability among pathologists. ADH lesions can display heterogeneity in their presentation, making it challenging to establish consistent criteria for diagnosis. Variability in architectural and cytological patterns within ADH specimens adds complexity to the diagnostic process. Histopathological variability in ADH diagnosis can lead to discordance in treatment decisions, with some lesions being upgraded upon surgical excision.[2,6,7,9,13] Standardizing histological criteria and improving interobserver agreement are ongoing challenges.

Upgrade Rates to Carcinoma Upon Excision

One of the major controversies in ADH management is the variability in upgrade rates to carcinoma upon excision. Studies have reported a wide range of upgrade rates, with some indicating a significant risk of underlying malignancy.[11] This inconsistency raises questions about the necessity of surgical excision for all ADH cases. Research has attempted to identify factors associated with a higher risk of upgrade, such as lesion size and radiologic features, but no definitive predictors have been established.[4] Addressing this issue is crucial to avoid unnecessary surgeries while ensuring the early detection of carcinoma when present.

Risk Prediction Models and Stratification

Efforts have been made to develop risk prediction models and stratification tools to better guide ADH management. These models aim to differentiate between low-risk and high-risk ADH lesions, potentially reducing the number of surgeries performed. However, the development of accurate risk prediction models remains a complex challenge.[4] Variables such as patient age, family history, radiologic characteristics, and molecular markers have been explored, but no single model has gained widespread acceptance. More research is needed to refine and validate these models to ensure their clinical utility.

Molecular Characterization for Risk Assessment

Molecular characterization has emerged as a promising avenue for assessing the risk associated with ADH. Studies have explored various molecular alterations and genetic profiling techniques to distinguish between low-risk and high-risk ADH lesions.[5,17] Molecular markers such as Ki-67 (Mib1), E-cadherin, miRNAs, lncRNAs, and circRNAs have been investigated for their potential to predict progression to carcinoma. Additionally, markers like tumor-infiltrating lymphocytes (TILs), immune checkpoints, and tumor mutational burden (TMB) have shown promise in risk assessment.[1] Integrating molecular characterization into risk assessment may improve the precision of ADH management and reduce unnecessary surgeries.

Molecular characterization holds promise for refining risk assessment, but further research is needed to establish standardized criteria and tools for stratifying ADH cases. Addressing these challenges is essential for optimizing patient care and minimizing the potential harms associated with ADH management.

CLINICAL MANAGEMENT AND TREATMENT

The current standard of care for ADH predominantly involves surgical excision following core needle biopsy. When ADH is identified through biopsy, excision is recommended due to concerns about the risk of underlying carcinoma.[4] This approach aims to ensure that any potential malignancy is appropriately addressed and reduces the risk of overlooking invasive cancer.

Recent research has explored the potential for risk stratification in ADH management. Efforts have been made to identify factors that can predict the likelihood of upgrading to carcinoma upon excision. For example, a meta-analysis involving 6458 ADH cases confirmed that surgical excision is recommended for all patients with ADH, highlighting the challenges of identifying factors that can safely omit surgery.[4] Future research should continue to investigate whether specific clinical or molecular markers can reliably stratify risk and guide personalized treatment decisions.

Artificial intelligence (AI) and molecular markers offer promising avenues for refining ADH management. AI algorithms can assist in the analysis of mammograms and biopsy samples, potentially enhancing diagnostic accuracy and risk prediction. Additionally, molecular markers such as Ki-67 (Mib1) and others could aid in distinguishing low-risk from high-risk ADH lesions.[2] Integrating these technologies into clinical practice may help optimize treatment decisions and reduce unnecessary surgeries.

A critical challenge in ADH management is striking a balance between early detection and overtreatment. While identifying ADH is essential for early intervention, not all cases progress to invasive carcinoma. Overemphasizing aggressive surgical interventions can lead to overtreatment and unnecessary harm to patients. Hence, research should focus on refining risk assessment tools, including molecular and clinical markers, to differentiate between low-risk and high-risk ADH cases. This would enable more precise and individualized treatment strategies.[8]

In summary, the current standard of care for ADH involves surgical excision after diagnosis by core needle biopsy. However, alternative approaches and research directions are emerging, including risk stratification, AI applications, and the use of molecular markers. Striking a balance between early detection and overtreatment remains a key challenge in ADH management, highlighting the need for personalized and evidence-based approaches. Future research in these areas

holds the potential to improve patient care and outcomes in ADH management.

FUTURE DIRECTIONS

The landscape of research on ADH continues to evolve, with numerous opportunities for advancements in understanding, diagnosis, and management.

One promising avenue for future research involves advancing molecular profiling techniques to better characterize ADH lesions at a genetic and molecular level. Understanding the specific genetic alterations and molecular signatures associated with ADH could provide valuable insights into its progression to carcinoma. For instance, investigations into the activation of the Akt pathway in ADH, as indicated by overexpression of Akt, FKHR, mTOR, S6, and cyclin D1, could provide deeper molecular insights.[17]

Long-term prospective cohort studies are essential to gain a comprehensive understanding of ADH's natural history and its relationship with subsequent breast cancer development. These studies can help address critical questions regarding the risk of progression, recurrence, and optimal management strategies for ADH. Establishing large, prospective cohorts that can follow individuals with ADH over extended periods to track their outcomes and identify factors associated with progression is crucial.[5]

A central challenge in ADH research is identifying reliable biomarkers that can predict the likelihood of progression to invasive carcinoma. Developing such biomarkers could revolutionize risk assessment and guide personalized management strategies. Efforts to validate biomarkers like Ki-67 to accurately stratify ADH lesions based on their risk of progression should be prioritized.[2]

The future of ADH management lies in personalized approaches that consider an individual's risk profile and molecular characteristics of the lesion. This includes refining risk stratification strategies, incorporating AI and molecular markers, and implementing tailored treatment plans. Emphasizing the potential for personalized management of ADH, where not all cases may necessitate aggressive surgical interventions, is crucial.[8]

The field of ADH research is poised for significant advancements in understanding the condition's molecular basis, risk factors, and outcomes. Future studies should prioritize the development of molecular profiling techniques, long-term prospective cohorts, reliable biomarkers for progression risk, and personalized approaches to ADH management. These efforts promise to enhance patient care and refine clinical guidelines for ADH diagnosis and treatment, ultimately leading to improved outcomes for individuals with this condition.

CONCLUSION

ADH, a pre-malignant, high-risk lesion, exhibits epidemiological variations dependent on regional and demographic factors,3 underscoring the necessity for tailored management approaches. Non-modifiable risk factors, such as age and familial history,[13] emphasize the importance of personalized risk assessments. Modifiable factors, including lifestyle choices,[2] offer avenues for targeted preventive strategies, presenting opportunities for mitigating breast cancer risk. Histologically, ADH shares molecular characteristics with more aggressive lesions,[7] prompting questions about its potential role as a precursor. Additionally, projections reveal an alarming trend – an anticipated increase in ADH incidence.[1] This highlights the urgency of proactive risk management and the significance of ongoing research to address this evolving landscape.

These findings bear profound implications for clinical practice, necessitating personalized ADH management. A uniform approach is no longer tenable. Instead, clinicians must consider individual risk profiles, accounting for both non-modifiable and modifiable factors, to determine the most appropriate course of action for each patient. The exploration of diagnostic challenges,[4] upgrade rates,[11] and risk prediction models[5] underscores the need for refined risk assessment tools and stratification methods. Clinical decisions regarding ADH should be based on robust evidence and sophisticated risk assessment, supplanting standardized protocols. Moreover, the advent of molecular profiling techniques[14] and artificial intelligence holds promise for transformative progress in ADH management.[5] These technologies offer the potential for enhanced risk assessment, more precise predictions of carcinoma progression, and the customization of therapeutic strategies. Clinicians should stay abreast of these developments and consider their integration into clinical practice.

To provide optimal care for ADH patients, further research is imperative. Prospective studies tracking ADH's natural history, progression to carcinoma, and long-term patient outcomes are indispensable.[5] Such studies would furnish invaluable insights into the most effective management strategies and the true risk associated with this condition. Additionally, the pressing need for reliable biomarkers for carcinoma progression remains.[14] These biomarkers would not only enhance risk assessment but also guide treatment decisions, alleviating the burden of overtreatment for select patients. Collaboration among clinicians, researchers, and patients is significant for advancing ADH knowledge.[4] Multidisciplinary efforts can dismantle existing barriers and facilitate the development of comprehensive, patient-centric management strategies. Furthermore, the inclusion of patient perspectives in research and clinical decision-making is essential to ensure that ADH management aligns with patient values and preferences. The journey toward understanding and effectively managing ADH is a collective endeavor, and collaborative endeavors will pave the way for more personalized and precise interventions in the future.

ACKNOWLEDGEMENTS

Dr. Frank Chen's expertise and insights significantly contributed to the depth and breadth of this review. Evan Liu provided essential support in many

aspects, including literature search, critical discussion, manuscript editing, table design and English modifications. Additionally, Liu acknowledges his academic affiliation with Walt Whitman High School and clinical intern experience at Integrated Medical Care, LLC.
Authors do not have any conflict interest to declare.

REFERENCES

1. Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies - An Updated Review. Cancers 2021;13,4287:1-30.
2. Bellini C, Cucchiari J, Naro F, et al. Breast Lesions of Uncertain Malignant Potential (B3) and the Risk of Breast Cancer Development: A Long-Term Follow-Up Study. Cancers 2023;15,3521:1-15
3. Casaubon J, Niakan S, Vicks E, et al. The effect of delay of excisional biopsy on upstage rate for atypical ductal hyperplasia, flat epithelial atypia, intraductal papilloma, and radial scar. Breast Cancer Research and Treatment 2022;196:527-534.
4. Brem RF. Management of Breast Atypical Ductal Hyperplasia: Now and the Future. Radiology. 2020;294:11-13. https://doi.org/10.1148/radiol.2019192192.
5. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635-648.
6. Schiaffino S, Calabrese M, Melani EF, et al. Upgrade rate of percutaneously diagnosed pure atypical ductal hyperplasia: systematic review and meta-analysis of 6458 lesions. Radiology. 2020;294:76-86. doi:10.1148/radiol.2019190748.
7. Khoury T. Preneoplastic Low-Risk Mammary Ductal Lesions (Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Spectrum): Current Status and Future Directions. Cancers 2022; 14,507:1-20.
8. Pinder SE, Shaaban A, Deb R, et al. NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). Clinical Radiology 2018;73:682-692.
9. Elfgen C, Leo C, Kubik-Huch R, et al. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Virchows Archiv 2023;483:5-20.
10. Collins LC, Baer HJ, Tamimi RM, et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2007;109:180-187.
11. Kader T, Hill P, Rakha EA, Campbell IG, Gorringe KL. Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. Breast Cancer Research 2018;20:39:1-11.
12. Jessica LF, Caroline GC, Sabrina KS, Avani Y, Suneela V. Prevalence, Impact, and Diagnostic Challenges of Benign Breast Disease: A Narrative Review. International Journal of Women's Health 2023;15:265-778.
13. Ye Q, Wang J, Ducatman B, et al. Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer. Int. J. Mol. Sci. 2023;24,10561: 1-29.
14. Schnitt SJ. The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance. Mod Pathol. 2010;23(Suppl 2):S1-S9.
15. Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ Breast Cancer Res. 2003;5:R25-R35.
16. Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast—risk assessment and management options. N Engl J Med. 2015;372:78-89.
17. Bose S, Hedayati M, Spaeth J, et al. The Akt pathway in atypical ductal hyperplasia of the breast. Arch Pathol Lab Med. 2007;131:1357-1362.
18. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995 Jul;48:611-5. doi: 10.1136/jcp.48.7.611.
19. Larson PS, de las Morenas A, Cerda SR, Bennett SR, Cupples LA, Rosenberg CL. Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors.J Pathol. 2006 Jul;209:307-16. doi: 10.1002/path.1973
20. Gao Y, Niu Y, Wang X, Wei L, Lu S. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med (2009) 87:145-152.
21. Fu SW, Lee W, Coffey C, et al. miRNAs as potential biomarkers in early breast cancer detection following mammography. Cell Biosci. 2016 Jan 26;6:6. doi: 10.1186/s13578-016-0071-0. eCollection 2016.
22. Li L, Jin Y, Wang X, et al. Long noncoding RNA ENST00000508435 promotes migration of breast cancer via FXR 1. Cell Adh Migr. 2021 Dec;15:140-151.
23. Liu Z, Zhou Y, Liang G, et al. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR- 200c-3p. Cell Death Dis. 2019 Jan 22;10:55. doi: 10.1038/s41419-018-1287-1.